PharmaFocus Today – Page 22 – media

Cell | Ma Kaiyue et al. develop a new method for high-throughput functional identification of mutations

The analysis of pathogenic genetic variations has always been an important challenge in the field of human genetics. Single nucleotide mutations in genes related to Mendelian genetic diseases should be the easiest type of mutation to study in human genetics. However, for many disease genes, the clinical importance of at least half of single nucleotide mutations has not been determined, seriously affecting the diagnostic efficiency of genetic diseases, especially rare genetic diseases. Deep mutational screening (DMS) refers to a research method that generates large-scale gene variations through saturation mutagenesis and then studies genetic variations in cell lines through high-throughput methods. This method can greatly accelerate the diagnosis of genetic diseases and deepen our understanding of the clinical importance of single nucleotide mutations. However, the cost and complexity of current deep mutation screening methods hinder their widespread application in clinical research. On September 25, 2024, Monkol Lek’s team from Yale ...
- Source: BioArt
- 84
- October 2, 2024
Nature | Fate selection of CD8+CAR T driven by asymmetric division

The long-term existence of CAR T is closely related to its clinical treatment efficacy, and long-life memory CAR T provides continuous immune monitoring to prevent tumor recurrence [1,2]. Model animal studies have found that asymmetric cell division (ACD) is one of the important mechanisms for memory formation in CD8+T cells [3,4]. The daughter cells derived from parental cell division, which are close to antigen-presenting cells (APCs), inherit immune synapses and are more likely to differentiate into short-lived effector T cells (Teff). In contrast, distal terminal cells differentiate into long-lived memory T cells with unique transcriptional, epigenetic, and metabolic characteristics (see BioArt report: Expert review of epigenetic strategies for improving T cell function by Guo Ao/Huang Hongling/Chi Hongbo/Douglas Green, etc.) [4-6]. Given the broad prospects of CAR T for cancer treatment, researchers have maintained a strong interest in the phenotype and memory formation of CAR T over the past decade. However, ...
- Source: Wind BioArt
- 78
- October 1, 2024
PNAS | Chen Junjie/Jiang Kuirong/Feng Xu/Jiang Dadi Team Collaborates to Reveal the Key Role of MGA in Tumor Immune Escape

Immune escape is one of the important features of cancer progression and a core challenge that affects the effectiveness of immunotherapy. Although immune checkpoint inhibitors (ICI) have achieved significant success in certain cancers, the overall response rate in solid tumors is still very limited. Exploring the mechanism of tumor immune escape in depth, discovering new targets, and improving ICI efficacy through combination therapy have become one of the key directions of current tumor immune research. On September 19, 2024, Professor Jiang Kuirong and Professor Feng Xu from the First Affiliated Hospital of Nanjing Medical University, together with Professor Chen Junjie and Professor Jiang Dadi from the MD Anderson Cancer Center of the University of Texas in the United States, published a research paper entitled In vivo CRISPR screens identify Mga as an immune target in triple negative breast cancer online on PNAS magazine, systematically expounded the core route of immune ...
- Source: BioArt
- 76
- October 1, 2024
A large number of pharmacies have withdrawn from medical insurance

So far, a large number of pharmacies have withdrawn from medical insurance. In September alone, Inner Mongolia has inspected 636 designated medical institutions and 1,661 retail pharmacies, imposed administrative penalties on 34, and suspended or terminated medical insurance agreements for 1,023; Xinjiang terminated the medical insurance service agreements of 162 designated medical institutions; 3 retail pharmacies in Tongling, Anhui terminated the medical insurance service agreements, and 1 medical institution in Yongxin, Jiangxi cancelled its medical insurance designated qualification… Earlier, similar situations also occurred in pharmacies in Zhoukou, Henan, Heyuan, Guangdong, Dezhou, Shandong, Fangshan, Beijing, Shaoyang, Hunan, Kunshan, Jiangsu, etc. The reasons for pharmacies to withdraw from the medical insurance service agreement vary, most of which are “actively applying”, “due to their own business reasons”, “illegal and irregular”, “due to failure to handle relevant procedures, no incurrence or approval of settlement expenses for more than six months”, etc. Pharmacies have ...
- Source: https://mp.weixin.qq.com/
- 64
- October 1, 2024
AstraZeneca, change is only for health with her

Cancer is one of the major public health problems facing China and the world. With the aging of China’s population and changes in lifestyle, the incidence of malignant tumors continues to increase. According to the latest data from the National Cancer Center based on tumor registration and follow-up monitoring, there will be 4.8247 million new cases of malignant tumors in China in 2022, and the total number of deaths will reach 2.5742 million1. Malignant tumors are one of the major diseases that threaten the health of Chinese residents. The lifetime risk of cancer among Chinese people is 28.9%2. China has been on the road to fighting cancer. The “Healthy China 2030” Planning Outline clearly states that by 2030, chronic disease health management will be achieved for the entire population and throughout the life cycle, and the overall 5-year cancer survival rate will increase by 15%3; the Cancer Prevention and ...
- Source: https://mp.weixin.qq.com/
- 67
- October 1, 2024
The “No.1 Chinese hepatitis C drug” is looking for a new engine

Recently, Ascletis announced that its independently developed small molecule GLP-1R agonist ASC30 is undergoing two Phase I clinical trials in the United States for the treatment of obesity with monthly subcutaneous injections and daily oral tablets. With the launch of these two Phase I clinical trials, Ascletis has officially entered the field of weight loss drugs. This is another highlight of the pipeline after Ascletis announced in April this year that it would focus on the development of core non-alcoholic steatohepatitis (NASH) drugs. Urgent need for a new engine Like most biotechs, Ascletis has also been moving forward by trial and error. However, Ascletis is luckier than most biotechs. It has become famous for its first local original hepatitis C drug Ganovo, which not only broke the monopoly of multinational companies such as Gilead, AbbVie, Bristol-Myers Squibb, and Merck in the domestic hepatitis C drug market, ...
- Source: https://news.yaozh.com/archive/44305.html
- 69
- October 1, 2024
A Rehearsal for Overcoming AIDS

Starting in June 2024, global scholars concerned with HIV prevention will focus their attention on Gilead’s antiviral drug, lenacapavir. At that time, Gilead released the latest data from the PURPOSE 1 trial, which demonstrated that lenacapavir, when administered via two annual injections, resulted in zero infections compared to daily oral PrEP medications. This suggests that, in the absence of successful vaccine development, lenacapavir could potentially serve as a long-lasting preventive alternative. However, whether the results of the PURPOSE 1 trial were a coincidence or a certainty remains unanswered. In September, Gilead further presented results from the PURPOSE 2 trial, indicating a higher likelihood of certainty. The results showed that 99.9% of participants in the lenacapavir group did not contract HIV, representing a 96% reduction in infection risk compared to the placebo group. This might signal that we are approaching an era of highly effective HIV prevention. 01 / The ...
- Source: https://caifuhao.eastmoney.com/news/20240925115315100512370?from=guba&name=5YyW5a2m5Yi26I2v5ZCn&gubaurl=aHR0cHM6Ly9ndWJhLmVhc3Rtb25leS5jb20vbGlzdCxiazA0NjUsOTksai5odG1s
- 64
- October 1, 2024
Merck’s first GMP grade cell culture medium production line in China has been commercialized and put into operation

Merck, a globally leading technology company, announced on July 12th that it has successfully commercialized its first GMP grade cell culture medium (CCM) production line in China. Merck has invested approximately 6.6 million euros in its manufacturing base located in Nantong, an industrial hub in the Yangtze River Delta region, in an effort to meet the growing demand in the Chinese market for high-quality customized cell culture media (used in fields such as biopharmaceuticals, vaccines, and new therapies). This localized commercial production can enable Chinese customers to reliably and efficiently obtain Merck’s highly reputable customized cell culture medium products and services. With its rich and professional formula experience and knowledge, Merck can produce high-quality customized cell culture media and innovative solutions based on specific formulas, ensuring batch uniformity and production efficiency of products. Merck Life Sciences China Managing Director Wu Bo said, “This investment further expands Merck’s business territory and ...
- Source: drugdu
- 95
- September 30, 2024
Jianjia Robot applies to withdraw its IPO application documents

On September 26th, the Shanghai Stock Exchange announced that Hangzhou Jianjia Robot Technology Co., Ltd. (hereinafter referred to as Jianjia Medical) has applied to withdraw its application for listing and therefore decided to terminate the review of its public offering of shares and listing on the Science and Technology Innovation Board. It is reported that Jianjia Robot applied for an IPO on the Science and Technology Innovation Board on April 2, 2023. After a round of inquiries, the Shanghai Stock Exchange reviewed and focused on issues such as orthopedic and dental implant surgical robots, market space, and core technologies. It takes one and a half years from application to termination. Yesterday, Jianjia Robot terminated its IPO, and another equipment company’s attempt to go public failed. The winter of IPO for equipment companies continues. When will spring come? Jianjia Robot has great potential for the future Jianjia Robot was founded in ...
- Source: drugdu
- 96
- September 30, 2024
What Are Its Treatment Prospects?

Recently, according to publicly available information from the Center for Drug Evaluation (CDE) of the National Medical Products Administration, the technetium-99m ([99mTc]) hydrazinonicotinamide polyethylene glycol RGD peptide injection (referred to as “99mTc-3PRGD2”) developed by Ruidiao Pharmaceuticals has been included in the priority review list. This also applies to the injection of toluenesulfonate hydrazone nicotinamide polyethylene glycol RGD peptide. 99mTc-3PRGD2 is a radiolabeled drug conjugate (RDC) independently developed by Ruidiao Pharmaceuticals. It is the first class I new drug for radiologic diagnosis in nuclear medicine in China and the world’s first broad-spectrum tumor imaging agent for SPECT imaging. Notably, the success of this drug’s development will change the current technical status and conventional understanding that SPECT/CT imaging technology in nuclear medicine cannot be used for tumor diagnosis, staging, and efficacy evaluation. According to Ruidiao Pharmaceuticals, 99mTc-3PRGD2 targets integrin and specifically binds to the integrin αvβ3 receptor on tumor neovascularization, demonstrating high ...
- Source: drugdu
- 75
- September 30, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.